PRMT5 and hematologic disorder: Inhibitors directed against PRMTs type I, i.e., PRMT1, CARM1, PRMT5, and PRMT7, have been tested on hematological malignancy models and have shown a significant decrease in malignant cell proliferation and an increased apoptosis.